|
|
|
|
|
|
|
|
|
|
Previous: RENAISSANCERE HOLDINGS LTD, POS AM, 1997-12-18 |
Next: BROTHERS GOURMET COFFEES INC, 8-K, 1997-12-18 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 1997
Lynx Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware 94-3161073
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
0-22570
(Commission File Number)
3832 Bay Center Place
Hayward, CA 94545
(Address of principal executive offices) (Zip Code)
(510) 670-9300
(Registrant's telephone number, including area code)
Total number of pages: 4
Page 1 of 4
<PAGE>
Item 5. Other Events
To demonstrate compliance with the requirements of the National Association of
Securities Dealers in connection with the Company's proposed Nasdaq National
Market listing application, attached hereto as Exhibits 99.1 and 99.2 are the
Company's unaudited Condensed Consolidated Balance Sheet and Condensed
Consolidated Statement of Operations for the period ended November 30, 1997.
Item 7. Financial Statements and Exhibits
(a) Financial statements of businesses acquired
none
(b) Pro forma financial information
none
(c) Exhibits
99.1 Lynx Therapeutics, Inc. unaudited Condensed Consolidated Balance
Sheet for the period ended November 30, 1997
99.2 Lynx Therapeutics, Inc. unaudited Condensed Consolidated
Statement of Operations for the eleven months ended November 30,
1997
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Lynx Therapeutics, Inc.
-----------------------------------
(Registrant)
December 18, 1997 /s/ Edward C. Albini
- --------------------------- -----------------------------------
(Date) Edward C. Albini
Chief Financial Officer
(Principal Financial and Accounting
Officer)
Page 2 of 4
Exhibit 99.1
Lynx Therapeutics, Inc.
CONDENSED CONSOLIDATED BALANCE SHEET
(In thousands)
November 30,
1997
--------
(Unaudited)
Assets
Current assets:
Cash and cash equivalents $ 11,887
Short-term investments 14,279
Accounts receivable 110
Other current assets 181
--------
Total current assets 26,457
Property and equipment:
Leasehold improvements 3,790
Laboratory and other equipment 3,524
--------
7,314
Less accumulated depreciation and amortization (3,475)
--------
Net property and equipment 3,839
Notes receivable from employees 205
--------
$ 30,501
========
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 147
Accrued compensation 291
Accrued professional fees 149
Deferred revenue from related parties - current 2,521
Other accrued liabilities 374
--------
Total current liabilities 3,482
Deferred revenue from related parties - long-term 0
Other noncurrent liabilities 176
Stockholders' equity:
Preferred stock 27,189
Common stock 42,702
Notes receivable from stockholders (460)
Deferred compensation (1,513)
Unrealized gain on marketable securities (1)
Accumulated deficit (41,074)
--------
Total stockholders' equity 26,843
--------
$ 30,501
========
Page 3 of 4
Exhibit 99.2
Lynx Therapeutics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Eleven Months Ended
November 30,
1997
--------
Net revenues:
Revenues from collaborative arrangements
with related parties $ 3,908
Other revenues 294
--------
Total revenues 4,202
Operating expenses:
Research and development 12,556
General and administrative 1,792
--------
Total operating expenses 14,348
--------
Income/(loss) from operations (10,146)
Interest income 591
--------
Net income/(loss) $ (9,555)
========
Net income/(loss) per share $ (2.60)
========
Shares used in per share computation 3,675
========
|
|